Business Description
![Equillium Inc Equillium Inc logo](https://static.gurufocus.com/logos/0C0000BITS.png?14)
Equillium Inc
NAICS : 325412
SIC : 2834
ISIN : US29446K1060
Description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 44.9 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.63 | |||||
Beneish M-Score | -0.23 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.1 | |||||
3-Year EPS without NRI Growth Rate | 36.2 | |||||
3-Year FCF Growth Rate | 19.8 | |||||
3-Year Book Growth Rate | -39 | |||||
Future 3-5Y EPS without NRI Growth Rate | -30.93 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 95.3 | |||||
9-Day RSI | 77.82 | |||||
14-Day RSI | 59.27 | |||||
6-1 Month Momentum % | -17.98 | |||||
12-1 Month Momentum % | -17.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.91 | |||||
Quick Ratio | 1.91 | |||||
Cash Ratio | 1.45 | |||||
Days Sales Outstanding | 37.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | 30.23 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -34.85 | |||||
Net Margin % | -32.01 | |||||
FCF Margin % | -59.66 | |||||
ROE % | -48.9 | |||||
ROA % | -21.67 | |||||
ROIC % | -78.08 | |||||
ROC (Joel Greenblatt) % | -915.91 | |||||
ROCE % | -39.22 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 1.68 | |||||
PS Ratio | 0.86 | |||||
PB Ratio | 1.55 | |||||
Price-to-Tangible-Book | 1.55 | |||||
EV-to-EBIT | -0.04 | |||||
EV-to-EBITDA | -0.04 | |||||
EV-to-Revenue | 0.01 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | -0.02 | |||||
Price-to-Net-Current-Asset-Value | 1.63 | |||||
Price-to-Net-Cash | 3.32 | |||||
Earnings Yield (Greenblatt) % | -2500 | |||||
FCF Yield % | -69.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Equillium Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 37.894 | ||
EPS (TTM) ($) | -0.36 | ||
Beta | 1.89 | ||
Volatility % | 232.67 | ||
14-Day RSI | 59.27 | ||
14-Day ATR ($) | 0.073331 | ||
20-Day SMA ($) | 0.716515 | ||
12-1 Month Momentum % | -17.57 | ||
52-Week Range ($) | 0.45 - 3.25 | ||
Shares Outstanding (Mil) | 35.25 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Equillium Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Equillium Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Equillium Inc Frequently Asked Questions
What is Equillium Inc(EQ)'s stock price today?
The current price of EQ is $0.93. The 52 week high of EQ is $3.25 and 52 week low is $0.45.
When is next earnings date of Equillium Inc(EQ)?
The next earnings date of Equillium Inc(EQ) is 2024-08-09 Est..
Does Equillium Inc(EQ) pay dividends? If so, how much?
Equillium Inc(EQ) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |